Biotech News
TG Therapeutics Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance
Raises full-year 2026 total global revenue guidance to approximately $1 billion, from approximately $950 million Raises full-year 2026 BRIUMVI U.S. net product revenue guidance to approximately $915–920 million, from $890–905 million Third-quarter 2026 total global revenue of approximately $260
